Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies.
about
Development of Novel Immunotherapies for Multiple MyelomaSystems biology of vascular endothelial growth factorsVascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.POEMS syndrome, calciphylaxis and focal segmental glomerulosclerosis - VEGF as a possible link.The significance of immunohistochemistry in the diagnosis and therapy of neoplasms.Thalidomide for the treatment of relapsed and refractory multiple myeloma.Expression and correlation of CD44v6, vascular endothelial growth factor, matrix metalloproteinase-2, and matrix metalloproteinase-9 in Krukenberg tumorVEGF blocking therapy in the treatment of cancer.Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.Novel therapies for patients with chronic myeloid leukemia.Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis.Angiogenic switch in multiple myeloma.Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.Autocrine VEGF loops, signaling pathways, and acute leukemia regulation.Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation.Blockade of NF-κB nuclear translocation results in the inhibition of the invasiveness of human gastric cancer cells.Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice.Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma.Transcriptional targeting of tumor endothelial cells for gene therapy.Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse modelTargeting the vascular endothelial growth factor in hematologic malignancies.Angiogenesis and multiple myeloma.Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesisDownmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis.Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.Effects of vascular endothelial growth factors and their receptors on megakaryocytes and platelets and related diseases.High density of tryptase-positive mast cells in patients with multiple myeloma: correlation with parameters of disease activity.Endothelial progenitor cells in multiple myeloma neovascularization: a brick to the wall.
P2860
Q28066890-246CE4B8-32D4-4A10-8181-AF34D14F218BQ30438979-2A8BA819-0BA6-4A2D-A7F3-1B25D5497E56Q33874179-9FD63F2F-98EA-418F-9735-4898DF3E94BCQ34484613-23896C8E-DCD8-487B-B1D2-CC0954CD180EQ34602545-594BEF7D-53F3-460C-B278-AA2143F1D229Q34782279-26EA59A2-AA18-4CCC-B9AB-2B4814C98592Q35064517-26D88D2E-43AA-4F28-859B-C8B6735B3F55Q35093616-78791FA3-6C52-4992-AF0A-AF9BE0E401C2Q35175287-AAFD15AF-5C24-4DB0-B98B-CD114026655EQ35728742-A72FD6B9-FA2C-40D8-8253-AFFCA0D64321Q35782469-718442C2-7350-4E21-A9D3-98FAFE8F55DEQ36069477-4213A3B6-4EF9-4465-BE98-9A55DB719F4DQ36788503-BEC668D9-8B4B-4F85-9CBD-29AE04628EB2Q36799838-999587FE-4753-46DC-A55F-FC53250A43B4Q37145879-EA6579C1-4F11-47A0-8742-DC55DBFCAA82Q37211667-808E6391-FDD8-4278-BEFB-65EBA8805A11Q37402452-FD1B66B3-E2F5-4AC0-ABAD-33D6A04FBA1BQ37413352-9DECD810-5247-4F5F-8B93-82ECA2C7E28FQ37459648-7A76EF7F-CE92-47B3-898B-8BB95D82A99CQ37718435-D9486CB9-D941-4227-B99F-3A92D3D81476Q38038645-F8E5D8AE-7404-45A9-8B77-6C40018AD8BAQ39696428-2CA7D5F3-5380-4D5F-A352-FC8D4F6BBD66Q40467361-FF1E076D-61F1-49B6-9692-D93029D8EC14Q42455980-9257299D-20AB-4B8A-A6AE-38CD7C04D94EQ44746790-794AC867-4D2B-4E67-B471-5EF89C19737FQ47288480-A3E06E49-057D-4017-8324-3757AA9EDA48Q49047584-B674D5F6-A47F-42CC-8AED-1A33B53BD7DBQ52535430-B09DA30F-9054-4A60-A24B-801D414CE731
P2860
Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Expression of vascular endothe ...... er hematopoietic malignancies.
@ast
Expression of vascular endothe ...... er hematopoietic malignancies.
@en
Expression of vascular endothe ...... er hematopoietic malignancies.
@nl
type
label
Expression of vascular endothe ...... er hematopoietic malignancies.
@ast
Expression of vascular endothe ...... er hematopoietic malignancies.
@en
Expression of vascular endothe ...... er hematopoietic malignancies.
@nl
prefLabel
Expression of vascular endothe ...... er hematopoietic malignancies.
@ast
Expression of vascular endothe ...... er hematopoietic malignancies.
@en
Expression of vascular endothe ...... er hematopoietic malignancies.
@nl
P1433
P1476
Expression of vascular endothe ...... er hematopoietic malignancies.
@en
P2093
Bellamy WT
P304
P356
10.1016/S0093-7754(01)90023-5
P577
2001-12-01T00:00:00Z